NCT00514709View on ClinicalTrials.gov

Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

1,843

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions
DiphtheriaTetanusPertussisHepatitis BInfluenza
Interventions
BIOLOGICAL

DTaP-HB PRP~T Combined Vaccine

0.5 mL, Intramuscular (IM)

BIOLOGICAL

DTaP-HB-PRP~T vaccine

0.5 mL, IM

BIOLOGICAL

Oral Polio Vaccine

Oral co-administered with study vaccine.

Trial Locations (7)

Unknown

City of Muntinlupa

City of Muntinlupa

City of Muntinlupa

City of Muntinlupa

City of Muntinlupa

City of Muntinlupa

City of Muntinlupa

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00514709 - Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants | Biotech Hunter | Biotech Hunter